Pharma Focus Asia

Thermo Fisher Invests US$ 50 million to Expand Bioproduction Capabilities

Thermo Fisher Scientific announced that it is investing US$50 million in its global bioproduction capabilities.

Features:

The Bioproduction capabilities will provide additional capacity for manufacturing single-use Bioprocess Container (BPC) systems.

Thermo Fisher's single-use bioprocess container systems are used for sterile liquid-handling applications.

These technologies help to increase productivity and ensure quality in the production of biological drugs.

In the UK, company is supposed to expand assembly capacity and add bioprocess container manufacturing systems. By this expansion, Europe will experience shorten leads time and improved global efficiency.

In the US, Thermo Fisher plans to expand cleanroom space for bioprocess container chambers and related assembly production processes in Logan, Utah, and also, in Millersburg, Pennsylvania.

The expansions are expected to be completed by the end of 2020.

Specifications:

NameThermo Fisher Scientific
LocationUK and USA
TypeExpansion
Estimated BudgetUS$50 million
ScheduleScheduled to be operational by 2020
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference